H-CYTE (OTCMKTS:HCYTD) Shares Down 49.5% – Should You Sell?

H-CYTE, Inc. (OTCMKTS:HCYTD) was down 49.5% during mid-day trading on Thursday. The stock traded as low as $2.02 and last traded at $2.02. 400 shares changed hands during mid-day trading, an increase of 288% from the average session volume of 103 shares. The stock had previously closed at $4.00.

H-CYTE Stock Performance

The company’s 50 day moving average price is $2.02 and its 200-day moving average price is $2.02.

H-CYTE Company Profile

H-Cyte, Inc is a clinical-stage biotechnology company focused on developing regenerative cell therapies for chronic pulmonary and respiratory diseases. Its primary investigational product, H-Cyte therapy, is designed to use a patient’s own cells in an effort to support lung repair and improve respiratory function.

The company has focused its research and development activities on conditions such as chronic obstructive pulmonary disease, emphysema and other serious lung disorders. H-Cyte’s therapies remain investigational, and their safety and effectiveness depend on the results of clinical development and regulatory review.

H-Cyte is based in the United States and has pursued clinical and commercial development of its cell-based technology for patients with significant respiratory disease.